Fibronectin-Binding Peptides for Stable Tumor and Fibrosis Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing diagnostic and therapeutic agents targeting fibronectin in tissues associated with increased fibronectin content, such as cancer and fibrosis, face challenges including poor stability in blood plasma, rapid degradation, and inefficient targeting and retention in target tissues.
Innovation Solution
A composition comprising fibronectin-binding peptides (FnBPs) linked to diagnostic or therapeutic agents, which selectively target fibronectin subunits Fnl 2-5, demonstrating high plasma stability and prolonged retention in fibrosis and tumor tissues, allowing effective tissue penetration and accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing diagnostic and therapeutic agents are used to target fibronectin in tissues, then targeting capability is achieved, but stability in blood plasma is poor and rapid degradation occurs
Solution Approach 1:
The patent employs peptide molecules with specifically optimized amino acid sequences and structural parameters that inherently resist proteolytic degradation in blood plasma while maintaining affinity for fibronectin. The peptide design incorporates stable secondary structures and resistant amino acid compositions that extend plasma half-life without sacrificing target binding capability.
Solution Approach 2:
The invention uses composite peptide structures that combine multiple functional domains: a fibronectin-binding domain with high affinity and specificity, and stabilization domains that protect against degradation. These composite peptide constructs achieve both plasma stability and prolonged tissue retention simultaneously.
2Speed
If smaller molecules like peptides are used for targeting, then faster diffusion and targeting speed are achieved, but stability in blood plasma decreases leading to short half-life
Solution Approach 1:
The patent optimizes peptide molecular weight, charge distribution, and hydrophobicity parameters to achieve optimal balance between diffusion speed and plasma stability. The peptide sequences are engineered with specific amino acid compositions that enhance protease resistance while maintaining small size for rapid tissue penetration.
3Reliability
If antibodies are used for targeting fibronectin, then high affinity binding is achieved, but permeability and retention at target tissue are reduced due to large size
Solution Approach 1:
The patent segments the large antibody molecule into smaller peptide fragments that retain the essential fibronectin-binding functionality. These peptide segments diffuse more rapidly into tissues and are retained more effectively at the target site while maintaining sufficient binding affinity through optimized amino acid sequences.
Solution Approach 2:
The invention extracts only the critical fibronectin-binding domain from the full antibody structure, creating minimal peptide sequences that preserve target specificity and affinity while eliminating the size-related limitations of complete antibodies for tissue penetration and retention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The FnBPs enhance diagnostic and therapeutic efficacy by providing selective targeting and prolonged retention in fibrosis and tumor tissues, overcoming issues of stability and distribution in existing agents.
Implementation Method 1
The FnBPs enhance diagnostic and therapeutic efficacy by providing selective targeting and prolonged retention in fibrosis and tumor tissues
Data Source
Figure 1A~1C
Figure 2A~2E
Figure 3A~3D
AI summary
The present invention is directed to a composition comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic agent, a nucleic acid encoding a fusion polypeptide comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic polypeptide agent as well as a corresponding recombinant vector and host cell comprising such a nucleic acid and preferably expressing said fusion polypeptide. The invention also relates to a kit of parts comprising at least one fibronectin binding polypeptide (FnBP), at least one diagnostic or therapeutic agent, and optionally one or more chemical agents for linking the fibronectin binding polypeptide (FnBP) to the diagnostic or therapeutic agent. In addition, the present invention intends said composition, nucleic acid, vector, host cell and kit for use in the therapeutic or prophylactic treatment of a disease, preferably a disease associated with abnormal fibronectin accumulation such as cancer, fibrosis or immune diseases.